Skip to main content
. Author manuscript; available in PMC: 2022 Jul 3.
Published in final edited form as: Vaccine. 2019 Sep 20;37(44):6760–6767. doi: 10.1016/j.vaccine.2019.08.087

Table 2.

Diagnostic categories of non-death serious reports following Adenovirus Type 4 and Type 7 Vaccine, Live, Oral reports in U.S. military personnel to VAERS, October 2011 through July 2018.

Diagnostic category Military
(N = 21)
N (%)
Military
observational study4
(N = 17)
N (%)
Total
(N = 38)
N (%)
Nervous system disorders 14 (66.7) 3 (17.6) 17 (44.7)
Guillain Barré syndrome 10 2 12
HNPP1 2 0 2
Epilepsy 1 1 2
ADEM2 1 0 1
Immune system disorders 2 (9.5) 8 (47.1) 10 (26.3)
Anaphylactic shock 0 8 8
Hypersensitivity Type III reaction 1 0 1
Scleroderma 1 0 1
Injury and poisoning and procedural complications3 0 4 (23.5) 4 (10.5)
Infections and Infestations 1 (4.8) 0 1 (2.6)
Blood and lymphatic disorders 1 (4.8) 0 1 (2.6)
Musculoskeletal and connective tissue disorders 1 (4.8) 0 1 (2.6)
Cardiac disorders 0 1 (5.9) 1 (2.6)
Renal and urinary disorders 1(4.8) 0 1 (2.6)
Gastrointestinal disorders 0 1 (5.9) 1 (2.6)
Psychiatric disorders 1 (4.8) 0 1 (2.6)
1

HNPP = Hereditary Neuropathy with Liability to Pressure Palsy.

2

ADEM = acute disseminated encephalomyelitis.

3

Implicated medications: penicillin G and ibuprofen, pseudoephedrine, acet-aminophen for nonspecific symptoms.

4

Sentinel Surveillance Plan-FDA-mandated post-marketing study.